Differential effects of probenecid on the levels of endogenous PGF2 alpha and TXB2 in brain cortex.
Probenecid in single or repeated doses does not modify levels of PGF2 alpha and TXB2 in rat brain cortex. After administration of subconvulsant dose of pentamethylene tetrazole (PMT) PGF2 alpha increases sharply and rapidly declines subsequently, whereas the elevation of TXB2 is smaller but of longer duration. After probenecid pretreatment PGF2 alpha levels do not decline up to 30 minutes after the initial peak and are still elevated after 60 minutes. Levels of TXB2 tend to be reduced after pretreatment. Differences in transport process or in biosynthetic compartments for these arachidonic acid (AA) metabolites may account for the observed data.
D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism*; D008297:Male; D010433:Pentylenetetrazole / Q000494:pharmacology; D011339:Probenecid / Q000494:pharmacology*; D011460:Prostaglandins F / Q000378:metabolism*; D051381:Rats; D013929:Thromboxane B2 / Q000378:metabolism*; D013931:Thromboxanes / Q000378:metabolism*; D013997:Time Factors
D011460:Prostaglandins F; D013931:Thromboxanes; D013929:Thromboxane B2; D011339:Probenecid; D010433:Pentylenetetrazole